When it comes to winning biotech stocks this year, coronavirus vaccine developers automatically come to many investors' minds. However, one of the top-performing stocks in the sector is Northwest Biotherapeutics (OTC: NWBO) , which focuses on immunotherapies that treat cancer, and has returned a staggering 408% since January.
The main reason why investors are so excited about Northwest Biotherapeutics' prospects is that the company's 14-year-long phase 3 clinical trial to evaluate its one and only immunotherapy candidate, DCVax-L, as a treatment for glioblastoma, has concluded. Should you consider buying the stock in anticipation of the data release? Let's find out together.
Image source: Getty Images.
For further details see:
Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?